[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HN1997000079A - Analogos de indazol sustituido. - Google Patents

Analogos de indazol sustituido.

Info

Publication number
HN1997000079A
HN1997000079A HN1997000079A HN1997000079A HN1997000079A HN 1997000079 A HN1997000079 A HN 1997000079A HN 1997000079 A HN1997000079 A HN 1997000079A HN 1997000079 A HN1997000079 A HN 1997000079A HN 1997000079 A HN1997000079 A HN 1997000079A
Authority
HN
Honduras
Prior art keywords
analogs
indazole
replaced
present
invention refers
Prior art date
Application number
HN1997000079A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN1997000079A publication Critical patent/HN1997000079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANALOGOS DE INDAZOL SUSTITUIDO.
HN1997000079A 1996-06-25 1997-06-05 Analogos de indazol sustituido. HN1997000079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (1)

Publication Number Publication Date
HN1997000079A true HN1997000079A (es) 1997-12-26

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1997000079A HN1997000079A (es) 1996-06-25 1997-06-05 Analogos de indazol sustituido.

Country Status (43)

Country Link
US (1) US6040329A (es)
EP (1) EP0912558B1 (es)
JP (1) JP3152940B2 (es)
KR (1) KR20000022516A (es)
CN (1) CN1080260C (es)
AP (1) AP1025A (es)
AR (1) AR007456A1 (es)
AT (1) ATE244713T1 (es)
AU (1) AU716376B2 (es)
BG (1) BG64052B1 (es)
BR (1) BR9712782A (es)
CA (1) CA2258285C (es)
CO (1) CO4900056A1 (es)
CZ (1) CZ423398A3 (es)
DE (1) DE69723447T2 (es)
DK (1) DK0912558T3 (es)
DZ (1) DZ2254A1 (es)
EA (1) EA002274B1 (es)
ES (1) ES2201299T3 (es)
GT (1) GT199700075A (es)
HK (1) HK1018700A1 (es)
HN (1) HN1997000079A (es)
HR (1) HRP970350B1 (es)
HU (1) HUP9903009A3 (es)
ID (1) ID18579A (es)
IL (1) IL127036A (es)
IS (1) IS4910A (es)
MA (1) MA24225A1 (es)
MY (1) MY116915A (es)
NO (1) NO986103D0 (es)
NZ (1) NZ332752A (es)
OA (1) OA10934A (es)
PA (1) PA8432301A1 (es)
PL (1) PL330974A1 (es)
PT (1) PT912558E (es)
SI (1) SI0912558T1 (es)
SK (1) SK176598A3 (es)
TN (1) TNSN97108A1 (es)
TR (1) TR199802685T2 (es)
TW (1) TW434237B (es)
WO (1) WO1997049702A1 (es)
YU (1) YU60198A (es)
ZA (1) ZA975581B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
AU724549B2 (en) * 1996-09-04 2000-09-28 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
SK6262000A3 (en) * 1997-11-04 2002-03-05 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
CA2440842A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
CA2469939C (en) 2001-12-14 2012-06-19 Applied Research Systems Ars Holding N.V. Method of inducing ovulation using a non-polypeptide camp level modulator
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
DE60334243D1 (de) 2002-11-19 2010-10-28 Memory Pharmaceutical Corp Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren
SG168409A1 (en) 2003-04-18 2011-02-28 Memory Pharm Corp Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN101166733A (zh) 2004-10-15 2008-04-23 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EP1891060A2 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivatives as inhibitors of phosphodiesterase type-iv
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2778949C (en) * 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (es) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
EP0633776B1 (en) * 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
CZ120097A3 (cs) * 1994-10-20 1998-01-14 Pfizer Inc. Bicyklické tetrahydropyrazolopyridiny a farmaceutické prostředky na jejich bázi

Also Published As

Publication number Publication date
IL127036A0 (en) 1999-09-22
PA8432301A1 (es) 1999-12-27
YU60198A (sh) 1999-09-27
AU2785797A (en) 1998-01-14
NO986103L (no) 1998-12-23
PT912558E (pt) 2003-11-28
CA2258285C (en) 2002-11-26
CZ423398A3 (cs) 1999-12-15
DK0912558T3 (da) 2003-08-18
BR9712782A (pt) 1999-12-07
OA10934A (en) 2002-02-18
PL330974A1 (en) 1999-06-21
TNSN97108A1 (fr) 2005-03-15
ES2201299T3 (es) 2004-03-16
WO1997049702A1 (en) 1997-12-31
DZ2254A1 (fr) 2002-12-18
JPH11514668A (ja) 1999-12-14
ATE244713T1 (de) 2003-07-15
AP9701020A0 (en) 1997-07-31
IL127036A (en) 2001-06-14
CA2258285A1 (en) 1997-12-31
EP0912558A1 (en) 1999-05-06
BG64052B1 (bg) 2003-11-28
JP3152940B2 (ja) 2001-04-03
KR20000022516A (ko) 2000-04-25
EA002274B1 (ru) 2002-02-28
TR199802685T2 (xx) 1999-03-22
TW434237B (en) 2001-05-16
EA199801047A1 (ru) 1999-06-24
HUP9903009A3 (en) 2002-01-28
NZ332752A (en) 2001-04-27
MA24225A1 (fr) 1997-12-31
CN1223651A (zh) 1999-07-21
ID18579A (id) 1998-04-23
AR007456A1 (es) 1999-10-27
HRP970350B1 (en) 2003-04-30
AU716376B2 (en) 2000-02-24
US6040329A (en) 2000-03-21
HRP970350A2 (en) 1998-06-30
DE69723447T2 (de) 2003-12-24
EP0912558B1 (en) 2003-07-09
GT199700075A (es) 1998-12-04
MY116915A (en) 2004-04-30
DE69723447D1 (de) 2003-08-14
ZA975581B (en) 1998-12-24
CO4900056A1 (es) 2000-03-27
AP1025A (en) 2001-11-19
NO986103D0 (no) 1998-12-23
SI0912558T1 (en) 2003-10-31
SK176598A3 (en) 2000-06-12
CN1080260C (zh) 2002-03-06
BG103056A (en) 1999-10-29
IS4910A (is) 1998-11-27
HUP9903009A2 (hu) 2000-05-28
HK1018700A1 (en) 1999-12-30

Similar Documents

Publication Publication Date Title
HN1997000079A (es) Analogos de indazol sustituido.
HN1997000126A (es) Derivados de indazol
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
HN1998000132A (es) Combinaciones terapeuticas
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000036A (es) Compuesto de pirazina
HN1997000090A (es) Compuestos de piridilpirrol
GR960100438A (el) Νεα παρασιτοκτονα.
HN1997000023A (es) Derivados de lactama
HN1998000011A (es) Derivados de acidos arilsulfonilaminohidroxamicos
HN1997000166A (es) 1-arilpirazoles plaguicidas
HN1998000175A (es) Imidazotriazininas
HN1997000146A (es) Derivados de pirimidina biciclica condensada
HN1998000020A (es) Derivados de acido arilsulfonilhidroxamico.
HN1999000155A (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
HN1996000101A (es) Terapia combinada para la osteoporosis
HN1997000040A (es) Sal mesilatotrihidroto de 5-2-4-1,2 -benzoisotiazol -3 il 1- piperazinil etil -6 - cloro 13 dihidro 2h indol 2-ona.
HN1999000131A (es) Derivados del acido hidroxi pipecolato hidroxamico.
HN1998000124A (es) Terapia de combinacion
HN1998000030A (es) 2-amino-6-(4fenoxi-2-sustituido)-piridinas sustituidas
HN1998003689A (es) Azetidinas
HN1998000158A (es) Isoquinolinas
SE9801494D0 (sv) Novel use
HN1998000106A (es) Composiciones parenterales de alatroflaxacino
HN1998000028A (es) Otropisomeros de 3 heteroaril - 4 (3h) - quinazolinonas.